Oura Acquires AI-Native Primary Care Startup Counsel Health for $625 Million

By Hector Herrera | November 11, 2026 | Health

Oura, the company behind the biometric tracking ring worn by roughly 10 million people, agreed to buy Counsel Health — an AI-native primary care company — for $625 million, one of the largest health AI acquisitions of 2026. The deal signals that Oura is no longer content being a data collector. It wants to become a continuous care delivery platform.

What Happened

TechCrunch reported that Oura will acquire Counsel Health in a cash-and-stock transaction, though the precise split has not been disclosed. Counsel Health was founded in 2023 and built a clinical AI platform that handles patient triage, chronic condition management, and care routing — escalating cases to human clinicians when the AI determines intervention is needed. The company operates in 11 states and has processed more than 2 million care interactions.

Oura CEO Tom Hale described the acquisition as completing "the loop" between biometric signal and clinical response. The combined company will operate under the Oura brand.

Why This Matters

The smart wearable category has long promised to close the gap between consumer health tracking and clinical medicine. The gap has persisted because collecting biometric data is a solved problem — acting on it clinically is not. Oura's ring tracks sleep stages, heart rate variability, body temperature, respiratory rate, and activity with FDA-cleared accuracy. What it lacked was a care delivery layer: a system that could take an anomalous signal — say, a persistent elevated resting heart rate — and do something about it beyond pushing a notification to the user.

Counsel Health fills that gap. Its platform is built to respond, not just flag. Combined with Oura's continuous biometric stream, the vision is an always-on primary care system that monitors you passively and intervenes when data suggests it should.

The Strategic Logic

Why Counsel Health? Its existing payer relationships, state medical licenses, and clinical AI infrastructure would take years to replicate. Acquiring them accelerates Oura's path to operating as a licensed clinical entity rather than a consumer device company.

Why now? Two dynamics make this the right moment. First, employer-sponsored digital health benefits are under pressure to demonstrate ROI — continuous monitoring with actionable care intervention is a credible value proposition. Second, the FDA has signaled openness to AI-augmented care delivery models, reducing regulatory uncertainty for the combined company.

For consumers, the acquisition raises the possibility of a wearable that doesn't just warn you something is wrong but actively helps you respond — scheduling a care visit, adjusting a care plan, or flagging an anomaly to your care team automatically and in context.

For the healthcare industry, it marks another step toward AI-coordinated care delivery that operates outside traditional fee-for-service insurance and provider networks. Oura's subscription model and Counsel Health's per-member-per-month pricing are designed to align around keeping people healthy, not billing for visits.

What to Watch

Regulatory scrutiny is the near-term question. The FTC and state medical boards will examine how biometric data collected by a consumer device flows into a clinical decision system — and what disclosures consumers receive when that data influences a care recommendation. HIPAA compliance for the integrated platform will require careful architecture, particularly around data minimization and access controls.

Expect the deal to close in Q1 2027 pending review. The bigger story to track over the next 12 months: whether Oura's move catalyzes similar vertical integration among other wearable companies — Whoop, Garmin, and Samsung all have biometric data streams without clinical care delivery attached.

Source: TechCrunch